Imiquimod 5% Cream Use for the Treatment of Basal Cell Carcinomas in Elderly Patients,in Long-Term Care Facilities,Not Amenable to Surgical or Radiation Therapy

Abstract

Get full access to this article

View all access options for this article.

References

Canadian Cancer Society/National Cancer Institute of Canada. Canadian cancer statistics 2004. Toronto, Canada: 2004. Available at: www.NCIC.cancer.ca.

Health Canada. Healthy Living. Government of Canada. Available at: www.hc-sc.gc.ca (accessed January 30, 2006).

Beutner

Geisse

Helman

. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002–7.

Sauder

. New therapies for skin disease: Imiquimod and related compounds. J Cutan Med Surg 2001;5 Suppl 2:2–6.

Sterry

Rusicka

Herrera

. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinomas: Randomized studies comparing low frequency dosing with and without occlusion. Br J Dermatol 2002;147:1227–36.

Shumack

Robinson

Kossard

. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinomas: Comparison of dosing regimens. Arch Dermatol 2002;138:1165–71.

Geisse

Caro

Lindholm

. Imiquimod 5% cream for treatment of superficial basal cell carcinoma. J Am Acad Dermatol 2004;50:722–33.

Tyring

Conant

Marini

. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol 2002;41:810–6.

Gollnick

Barona

Frank

. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: Interim 2-year results from an ongoing 5-year follow up study in Europe. Eur J Dermatol 2005;15:374–81.